Key Highlights

● Vaxcyte climbed solidly on Friday, trading at about $65.05 in the afternoon, with no company-specific announcement.

● Vaxcyte develops pneumococcal conjugate vaccines and is not a cancer-vaccine developer or named in the NIH plan.

● Moderna jumped $28.00 to $225.00, Novavax soared and BioNTech climbed to about $92.44 as Vaccine stocks moved together.

● Gainers outnumbered losers on the Nasdaq by 2,756 to 1,997, though trading Volume was below its recent average.

Vaxcyte (NASDAQ:PCVX) climbed solidly on Friday, trading at about $65.05 in the afternoon as vaccine developers rallied as a group. There was no company-specific announcement behind the move. Instead, the stock rose alongside peers after a media report put vaccines back at the top of biotech investors' minds.

The report said the National Institutes of Health plans a public-private campaign, beginning in December, to fast-track research into cancer vaccines and treatments. According to the report, the initial focus would be pancreatic, liver and colorectal cancers as well as some childhood tumors, with the goal of replicating the success of the Covid-19 vaccine effort.

A different kind of vaccine company

Vaxcyte's link to that story is indirect. The company develops pneumococcal conjugate vaccines, designed to protect against bacteria that cause pneumonia, meningitis and other serious infections. It is not a cancer-vaccine developer, and it was not named in connection with the NIH plan.

Even so, investors often trade vaccine companies as a basket when sentiment toward the field shifts. A visible government push into vaccines, even for a different disease area, can lift the whole group by signaling renewed public support and potential funding for vaccine research. That helps explain why a broad range of names moved on Friday.

Who else moved

Moderna (NASDAQ:MRNA) led the charge, jumping $28.00 to close at $225.00, its highest level since 2021, on the same day it officially joined the Nasdaq-100. Novavax (NASDAQ:NVAX) soared, BioNTech (NASDAQ:BNTX) climbed to about $92.44, and Arcturus Therapeutics (NASDAQ:ARCT) rose after Leerink Partners raised its price target to $19 from $13. Larger drugmakers including Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD) also gained.

Health care was among the S&P 500's strongest sectors on Friday, helped further by Humana (NYSE:HUM)'s rally after new Medicare star ratings. The sector also finished among the leaders for the week.

As reported, the NIH initiative is still a plan, and details on participating companies, funding and timelines have not been published. For a company like Vaxcyte, whose prospects rest on clinical data for its own vaccine candidates, Friday's gain reflected sector mood rather than a change in its own outlook.

Market backdrop

Stocks rose broadly. The Nasdaq Composite gained 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54, just shy of Tuesday's record close, and the Dow climbed 423.31 points to 51,654.95. Gainers outnumbered losers on the Nasdaq by 2,756 to 1,997, though trading volume across US exchanges was below its recent average.

The rate environment remains tough for growth-oriented biotech. The 10-year Treasury Yield held near a 24-year high, the Fed raised rates in September for the first time since 2023, and Fed Governor Christopher Waller said Thursday he anticipates additional hikes to bring Inflation back to the Fed's goal. "Strong Earnings combined with moderating inflation would offer the most supportive backdrop for equities," said Daniela Hathorn, a senior market analyst.

Official NIH Details and Vaxcyte's Own Clinical Updates Are the Next Items to Watch

Monday, October 12 is Columbus Day, with stocks open and bonds closed. September consumer prices are due Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank earnings run from October 13 to 16, and the Fed meets on October 27 and 28. Vaxcyte's prospects rest on clinical data for its own candidates, so any pipeline update will matter alongside official details of the NIH-linked plan before its expected December start.